Weekender: Vertex, needing research spark, finds promising results in small study of kidney disease drug

Signup | Forward Weekender Dec.​ 4,​ 2021 | A roundup of this week's most read stories

BROUGHT TO YOU BY — Guidehouse Explore the patient's digital journey How can digital solutions be optimally effective by engaging and empowering patients throughout their entire healthcare journey? Learn more.   Vertex, needing research spark, finds promising results in small study of kidney disease drug The biotech, which has been stung by recent clinical setbacks, plans to soon advance the medicine into late-stage testing. GSK hires away top Pfizer vaccine scientist Philip Dormitzer, who helped Pfizer develop shots for COVID-19, RSV and influenza, will become the British pharma's head of vaccine R&D next month. Regeneron warns its antibody drug may be less potent versus omicron While Regeneron is still testing its treatment against the variant, the biotech is readying contingency plans, including second-generation versions of its drug. Sponsored Content by Elemental Machines The State of LabOps In this inaugural report, Elemental Machines presents timely insights regarding the rapidly evolving future of LabOps, strategies to optimize lab operations and tools that warrant a place at the strategic table. Download the eBook. Blueprint, taking aim at larger drugmakers, becomes a biotech buyer A $250 million acquisition of startup Lengo Therapeutics has given Blueprint a lung cancer drug that could compete with medicines from Takeda and J&J. FDA panel, after debate, narrowly backs Merck COVID pill While agency advisers raised concerns over molnupiravir's modest benefits and potential risks, a majority felt the antiviral drug is a needed option for COVID-19 patients at high risk of severe disease. Recommended For You Improve your recommendations: click here to update your profile. Deep Dive Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them. After several family members had early heart attacks, Kathiresan vowed to understand why they happen. His research journey has changed medical practice and led to a new biotech startup, Verve Therapeutics, that seeks to prevent them. BROUGHT TO YOU BY — Galen What makes an acquisition the right fit for both companies? In their latest case study, find out what elements came together to drive success following Galen's acquisition of POA Pharma and what the future holds. Click here to download instantly. From Our Library Webinar - on demand Important ADME & Drug-Drug Interaction Considerations for Successful Drug Development Xenotech Webinar - on demand The Future of Biopharmaceutical Quality: A Focus on People, Process, and Proactive Risk Mitigation Samsung Biologics Trendline How cancer research is changing the pharma and biotech sectors Playbook Accelerating Biotech Discovery With High-Dimensional Biology and Bioinformatics BD Biosciences Playbook Critical & Time-Sensitive Cold Chain Shipments Best Practices Tive View all resources Best of What We're Reading The Wall Street Journal FDA Aims for Quick Review of Omicron Vaccines and Drugs STAT Califf asks Woodcock to stay in FDA leadership role if he’s confirmed Financial Times Fujifilm to double size of Teesside plant that makes Covid vaccine Evaluate Vantage Bridgebio sets its heart on besting Pfizer STAT Biden's new Covid plan: more boosters, free home testing, and 'monoclonal antibody strike teams' Reuters Australia's CSL in exclusive talks to buy Swiss Vifor Pharma - report Suggest a story we should read Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc. 1255​ 23rd Street NW, Suite 550, Washington,​ DC 20037. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip